Dedicated biopharma event to launch alongside CPhI WW 2018

A new event dedicated to biopharma is set to launch alongside next year’s CPhI Worldwide event, taking place in Madrid.

According to the event organisers, UBM, BioLive has been created after independent research identified a gap in the market for a global exhibition and content platform covering the bio manufacturing value chain.

This event will serve as a global hub for both upstream and downstream processing and manufacturing, connecting biotechs, big pharma and service providers including CDMOs and CROs from early stage development to commercial manufacturing and regulatory services. It will also feature biogeneric and bioinnovator audiences through to manufacturing and laboratory specialists.

“It’s a hugely exciting time for the bio industry globally and we expect rapid growth in what is now a maturing supply chain. Independent research showed a dissatisfaction amongst existing options, and we have identified that we can provide broader depth in bio manufacturing and processing, whilst capitalising on our collective portfolio strength to bring additional value by combining the small and large molecule worlds together with contract services,” commented Rutger Oudejans, brand director at UBM. He added, “It is firstly to provide an ecosystem to bring together the bio development and manufacturing sectors. But it also enables companies and professionals involved across the full pharma value chain of both small and large molecule to learn from each other and evolve new strategies to overcome the challenges in bio processing and manufacturing.”

Eric Langer, president and managing partner, BioPlan Associates added his support to events that facilitate collaboration, commenting: “This event has been developed to provide an opportunity for both bio and pharma executives to meet and exchange ideas, and to address key challenges the industry faces, including how to overcome supply chain, processing and manufacturing challenges. The industry needs an effective forum where it can centralize both bio and pharma partners who can now meet different parts of the global bio/pharma industry, especially as the bio manufacturing segment matures. Industry data suggests that biopharma can still learn much from small molecule pharma, and that is why this new event could provide unique perspectives that can advance the bio industry.”